GH Research PLC (GHRS)

NGM – Real Time Price. Currency in USD

28.22

+2.88 (11.37%)

At close: Jun 26, 2026, 4:00 PM EDT

27.75

-0.47 (-1.67%)

After-hours: Jun 26, 2026, 7:28 PM EDT

04.06.2026

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial,” has been published in The Journal of Clinical Psychiatry (DOI: 10.4088/JCP.25m16284).

20.05.2026

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling it remains to be seen how the drug stacks up against peers under real-world conditions.

15.05.2026

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

14.05.2026

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Updates Scientific Presentations and Publications In March 2026, the results of our Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry.

29.04.2026

GH Research Announces Pricing of $117.5 Million Underwritten Offering

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares are being offered by GH Research PLC.

20.04.2026

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has been backed by Republicans in Texas in recent years who argue in favor of ibogaine's success with veterans.

20.04.2026

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness.

Videos

No Data

There is no data to display

Press releases

04.06.2026

GH Research Announces Publication of Phase 2a Postpartum Depression Results

14.05.2026

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

29.04.2026

GH Research Announces Pricing of $117.5 Million Underwritten Offering

20.04.2026

GH Research PLC (GHRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

GH Research PLC (GHRS)

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Videos

No Data

Press releases

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Videos

No Data

Press releases

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Search stocks

GH Research PLC (GHRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

GH Research PLC (GHRS)

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Videos

No Data

Press releases

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Videos

No Data

Press releases

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness